New service – bi-specific antibodies!

Fusion Antibodies are proud to offer a new and unique service of generation of antibodies which are hybrids of two of your Therapeutic monoclonals.

With the recent press attention surrounding the first FDA approved bi-specific antibody; catumaxomab and the announcement of the Humanization of Fusion Therapeutics very own fsn1006 double-targeting antibody, there has never been a better time to combine the effects of your antibodies.

Fusion Antibodies have a long history of custom scFv and Fab fragment production and we are excited to offer this great new service to you.

For more details on Bi-Specific Antibody Production and for pricing please contact us today at or call us on +44(0) 28 9043 2800